

## Brucellosis underreporting in Greece: assessment based on aggregated laboratory data of culture-confirmed cases from public hospitals

Dougas G<sup>1</sup>, Mellou K<sup>1</sup>, Kostoulas P<sup>2</sup>, Billinis C<sup>3</sup>, Georgakopoulou T<sup>1</sup>, Tsiodras S<sup>1,4</sup>

<sup>1</sup>Zoonoses Unit, Hellenic National Public Health Organization, Athens

<sup>2</sup>Department of Veterinary Epidemiology, Faculty of Veterinary Science, University of Thessaly, Karditsa

<sup>3</sup>Department of Microbiology & Parasitology, Faculty of Veterinary Science, University of Thessaly, Karditsa

<sup>4</sup>4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens  
Greece

### Abstract

**Background:** *Brucella* spp. isolation is one of the mainstays of brucellosis diagnosis. Simultaneously, the true brucellosis disease rate may be underrepresented in notification systems. This study aims at assessing the nosocomial capacity for *Brucella* spp. isolation and the underreporting rate of brucellosis cases in Greece.

**Methods:** Data for *Brucella* spp. culture capacity and the number of isolations were collected annually from public hospitals nationwide, during 2015-2018. The number of unreported cases was estimated after subtracting the National Mandatory Notification System cases from the survey-captured isolations, matched by hospital and year.

**Results:** Feedback was provided by 112 public hospitals (response rate: 97.4 %). *Brucella* spp. isolation capacity was completely absent in 27.7 % of hospitals; during the four years of the study, 11.3 %, 13.9 %, 20.0 %, and 25.2 % of the hospitals had isolation competence for one, two, three, or four years, respectively. Underreporting assessment was possible in hospitals that declared at least one *Brucella* spp. isolation (n =35) and unreported cases were identified in 19 (54 %). A mean underreporting of 28.9 % of total cases was estimated for the whole period of the study ranging annually from 24.1 % to 35.0 %. The number of unreported cases per hospital ranged from one to 12 per year (median: 2, IQR: 5).

**Conclusions:** Interventions for improving diagnosis and reporting of the disease are recommended. Assessment of brucellosis underreporting by comparing raw numerical data of survey-captured isolations and officially notified cases lacks the case by case specificity, however, keeping required data to a minimum achieves high feedback rate from hospitals and provides a tentative estimation of the notification deficit. HIPPOKRATIA 2019, 23(3): 106-110.

**Keywords:** Brucellosis, *Brucella* spp., disease notification, public health surveillance, Greece, under-notification, clinical laboratory techniques

**Corresponding author:** Georgios Dougas, Hellenic National Public Health Organization, 3-5Agrafon str., 15123, Athens, Attiki, Greece, tel: +306972026826, e-mail: gdougas@med.uoa.gr; georgiosdougas@yahoo.com

### Introduction

The monitoring of zoonotic diseases of public health importance, the prompt response to outbreaks, and the health policy planning rely on efficient notification systems<sup>1</sup>. However, surveillance of communicable diseases may suffer from an underestimation of the true incidence rate. Failure to precisely record cases may stem from different levels of the surveillance process, at the community level by cases not seeking or reaching health providers, or at the health settings level by underdiagnosis or underreporting of cases<sup>2</sup>.

Brucellosis is endemic in Mediterranean countries<sup>3</sup>; as confirmation of diagnosis relies on specific laboratory methods, the laboratory capacity would be an essential component of the notification process<sup>4</sup>. Furthermore, the

true notification rate of the diagnosed cases cannot be estimated since the extent of underreporting is unknown<sup>5,6</sup>.

In Greece, brucellosis presents the highest notification rate among the European countries<sup>7</sup>. Brucellosis is a mandatorily notified disease, and the surveillance is based on the case definition laid down by the European Center for Disease Prevention and Control (2012/506/EC). The laboratory diagnosis entails the culture/isolation of the pathogen, the identification of specific antibodies, or the detection of *Brucella* spp. nucleic acid. However, only few studies are available for the hospitals' laboratory diagnostic capacity and the brucellosis underreporting in Greece<sup>8-10</sup>.

In this study, we present our findings on the public hospital laboratory capacity for *Brucella* spp. isolation

and an estimation of brucellosis underreporting based on the comparison between laboratory data and the cases reported at the National Mandatory Notification System (NMNS) in Greece for the period 2015-2018.

### Methods

A survey was conducted annually by the National Public Health Organization (NPHO) for the years 2015-2018 in the frame of an investigation of the diagnostic capacity and the efficiency of the disease surveillance regarding food-borne communicable diseases. In the first trimester of each year, a structured questionnaire, containing fields for the laboratory capacity of *Brucella* spp. isolation and the absolute number of positive cultures regarding the previous year was distributed to the laboratories of all Greek public hospitals. The questionnaire was accompanied by an official letter explaining the rationale of the study, i.e., identifying laboratory weaknesses and gaps in the disease surveillance. Incoming information on positive cultures was collected in the form of aggregated data without patient identifiers.

The officially recorded via the NMNS brucellosis cases were obtained by the registry of NPHO; the corresponding data included the hospital and the year of reporting, the methods, and the results of the laboratory diagnosis, without patient demographic data.

The underreporting rate was defined as the percentage of unreported cases against all known cases. Underreporting hospitals were defined as the ones with at least one unreported case. The culture capacity per local administrative unit (regional unit) was estimated based on the highest capacity in years, recorded in the public hospitals located in the respective regional unit.

Hospitals were characterized as urban and non-urban, and as academic and non-academic. The status of a hospital (urban/non-urban) was based on its location in an administrative unit characterized as “predominantly urban” by the European Statistical Office<sup>11,12</sup>; these locations in Greece include only the region of Attica and the regional unit of Thessaloniki. According to Eurostat, all other locations characterized as “intermediate” and “predominantly rural” were considered rural for the purposes of the study. A hospital satisfied the academic criterion if the infectious diseases department was supervised by the local university medical school.

In the analysis, survey records of hospital-years with at least one positive culture were selected and linked with the records of the respective hospital-years from the NMNS database. The net amount of unreported cases was calculated as the positive residue after subtracting all NMNS reported cases, regardless of the laboratory method for diagnosis used, from the respective survey-reported isolations (Figure 1).

The consistency of the underreporting rate on a hospital basis was investigated throughout the study period. Paired data per hospital were tested for differences across successive years for the presence or absence of underreporting (Cochran’s q test) and the magnitude of the underreporting rate (Wilcoxon signed-ranks test).



**Figure 1:** Venn schematic diagram. Estimated unreported brucellosis cases as the residue after subtracting the cases reported at the National Mandatory Notification System from the matched *Brucella* spp. survey-reported positive cultures, linked by hospital and year.

The association of the urban and the academic quality of the surveyed hospitals with the presence of underreporting was investigated (Chi-square test). Differences in the average underreporting rate among hospitals grouped by the presence or absence of urban and academic quality were determined (Mann-Whitney U test).

Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA), whereas QGIS Geographic Information System 2.18.28 (QGIS Development Team under GNU GPLv2 license) was utilized for geographical imaging. The significance level was set at 5 %.


### Ethical statement

The NPHO may publish reports and engage in studies concerning epidemiologic research using non-identifiable data of statistic nature. This study used only aggregated and non-identifiable surveillance data which do not qualify as personal data according to article 2, lit. A, Law 2472/1997 and the currently in force Regulation (EU) 2016/679 (General Data Protection Regulation), therefore no ethical approval was necessary.

### Results

Among the 115 public hospitals surveyed during 2015-2018, data was provided by 112 (97.4 %) for at least one year. Three hospitals did not provide feedback at all. An average of 85 hospitals per year (min 84 - max 90) replied, and among these, an annual average of 58 (min 53 - max 64) reported *Brucella* spp. isolation capacity. The total number of years with effective isolation capacity varied among hospitals, with 27.7 % not having such capacity at all during the study period (Table 1).

The culture capacity (years) also varied per local administrative unit [median: 3, interquartile range (IQR): 3], ranging from total absence (16 %) to isolation capacity during all four years of the study (35 %) (Figure 2).



**Figure 2:** Mean annual *Brucella* spp. isolation capacity per local administrative unit, Greece, 2015-2018.

**Table 1:** *Brucella* spp. isolation capacity of public hospitals in years, Greece, 2015-2018.

Isolation capacity (years)	Hospitals	(%)
0	31	(27.7)
1	13	(11.6)
2	16	(14.3)
3	23	(20.5)
4	29	(25.9)
	112	(100.0)

In total, 221 *Brucella* spp. isolations were received by 35 hospitals as survey-feedback. During the study period, 424 brucellosis cases were officially registered to the NMNS; among those, 167 were matched with the survey data by hospital and year of reporting, resulting in 70 linked records.


Overall, 68 unreported cases were captured during 2015-2018, raising the total brucellosis cases at 235 instead of the 167 registered in NMNS and revealed an underreporting rate of 28.9 % for the whole study period, ranging annually from 24.1 % to 35.0 % (Figure 3).

In total, 19 hospitals (54 %) were identified with at least one unreported case during 2015-2018 with the number of unreported cases ranging from 1 to 12 per hospital (median: 2, IQR: 5) (Table 2).

An annual average of eight public hospitals per year had unreported cases, representing 23 % (95 % confidence interval (CI): 9-37 %) of the total surveyed hospitals.

In public hospitals with at least one unreported case for the study period, the mean annual underreporting rate was estimated at 49 % (95 % CI: 33-66 %).

No significant differences regarding the presence, absence, or intensity of underreporting rate per hospital across the years were identified. The urban location and the academic property of hospitals were not associated



**Figure 3:** Underreporting rate (%) of brucellosis cases diagnosed at public hospitals (n =35), Greece, 2015-2018.

**Table 2:** Unreported brucellosis cases per public hospital, Greece, 2015-2018.

Unreported cases per hospital	Hospitals	(%)
0	16	(46)
1	8	(23)
2	3	(9)
3	1	(3)
5	2	(6)
6	2	(6)
7	1	(3)
10	1	(3)
12	1	(3)
	35	(100)

with the presence of unreported cases or significant differences in the average underreporting rate.

## Discussion

Significant brucellosis underreporting was identified even when estimating the minimum amount of possible unreported cases by eliminating overlapping records and estimating only the surplus of isolations for ensuring a unique registration for each case. The described approach for capturing underreporting differed from the standard methodology<sup>8,13</sup> because it required minimal information in the form of aggregated data. Possibly, the less required information contributed to the observed very high response rate among the participating public hospitals.

Brucellosis underreporting has been previously demonstrated in Greece; our results concur with the findings of Jelastopulu et al<sup>9</sup> of almost 25 % unreported cases during a 5-year study in one region in Greece whereas Avdikou et al<sup>10</sup> reported approximately 80 % underreporting rate, in a 2002-2004 regional study. Deficits in reporting of brucellosis cases have also been described in Turkey<sup>6</sup> (68 %), as well as in several other countries<sup>14</sup>. Considering the results presented by other researchers, we conclude that our findings of brucellosis underreporting in Greece fall within the expected range.

Noteworthy, the underreporting rate varied among hospitals but without significant variation for each hospital throughout the years, suggesting a hospital-specific behavior towards notification of communicable diseases. Researchers have attributed underreporting to the reluctance of the medical personnel to notify properly, due to disapproval or misinformation regarding reporting, to the increased hospital work burden, and the limited material and human resources for laboratory diagnosis or for accomplishing the notification tasks<sup>15-18</sup> whereas lack of appropriate training is also a critical factor<sup>19</sup>. The urban and/or academic profile of hospitals was not associated with underreporting of brucellosis, contrary to previous reports in Greece, regarding other mandatorily notifiable diseases<sup>8</sup>.

The study revealed that a significant proportion of brucellosis patients were diagnosed with culture but remained unregistered to NMNS. An intrinsic difficulty in culture reporting stems from the relatively long period of several days or weeks required for the culture/isolation outcome. In contrast, the serology methods produce prompt results, have considerably less bio-security concerns, and are widely available, even though they lack specificity<sup>20-22</sup>. We hypothesize that the unreported cases of our study were diagnosed only by means of *Brucella* spp. isolation without concurrent positive serology or polymerase chain reaction (PCR), and due to the comparatively long incubation period for finalizing the culture result, the momentum of notification was lost. Baldi et al<sup>23</sup>, and Serra and Viñas<sup>24</sup>, described that a proportion of brucellosis cases might be diagnosed by culture alone, with the serology tests remaining negative; Yagupsky<sup>25,26</sup> reported that *Brucella* spp. isolations might occur unexpectedly during routine incubation of clinical samples from patients without suspicion of brucellosis. Among registered cases, PCR was rarely used for diagnosis; only 12 (2.8 %) of the cases were PCR-confirmed during 2015-2018. However, due to the lack of relevant data, our hypothesis cannot be attributed to confirmation of brucellosis with positive cultures of *Brucella* spp. as a stand-alone method or combined with false-negative results of serology or PCR techniques.

Further investigation is required for identifying and addressing the reasons that lead to underreporting and for elucidating a possible correlation of culture-only diagnosis with lower reporting rates.

The analysis was based on comparing numbers of records from both survey and NMNS datasets, but a linkage on an individual case by case basis was not possible. The NMNS cases might have coincided with the ones of the survey but might have reflected other cases as well; a higher rate of a case by case matching would bring the study results closer to true underreporting.

Each *Brucella*-positive culture was assumed to correspond to a single case, and this represents a limitation of our study since no differentiation of cultures from the same patient was possible, and this would have led to an overestimation of the underreporting rate. Furthermore,

in Greece, the population is not registered at particular healthcare settings, and the same patient would visit more than one health care facilities for the same symptoms and thus provide more than one cultures. However, in accordance with the common practice, we presume that no additional cultures are utilized in the diagnosed patients with brucellosis for the same infection event; the physicians usually monitor the response to therapy with the clinical course and the aid of the antibody titer. Also, we consider that patients diagnosed and followed up at the local hospital rarely visit any other public hospitals for the same medical issue. Furthermore, even if patients have a preference to visit a different hospital than the local one, consistent behavior is anticipated, and introduced bias may affect the implicated hospitals but not the results of the study at a national level.

Recovered patients, presenting again with symptoms and with a positive culture, were regarded as new cases since relapse and re-infection are impossible to distinguish. Nevertheless, cultures are markedly less sensitive<sup>21</sup> in relapses than in the primary infection, whereas serology methods may be more suitable for identifying active disease in patients suspected for relapse<sup>27</sup>.

## Conclusions

A considerable deficit of the capacity to isolate *Brucella* spp. and a high underreporting rate were identified among public hospitals in Greece. The underreporting rate of brucellosis cases significantly varied among public hospitals, but each hospital had an invariable underreporting profile throughout the years. A partition of brucellosis cases might be refractory to reporting due to being exclusively diagnosed by isolation of the pathogen and the long time required to finalize the culture result. The reasons that lead to underreporting should be elaborately investigated and addressed. Assessment of brucellosis underreporting with the crude number of positive cultures yielded a high response rate from hospitals and provided a tentative estimation of the notification deficit but with a risk of underestimating the true notification deficit.

## Conflict of interest

Authors declare no conflicts of interest.

## References

1. Nsubuga P, White ME, Thacker SB, Anderson MA, Blount SB, Broome CV, et al. Public Health Surveillance: A Tool for Targeting and Monitoring Interventions. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al (eds). Disease Control Priorities in Developing Countries. 2<sup>nd</sup> Edition. World Bank & Oxford University Press, New York, 2006, 997-1016.
2. Gibbons CL, Mangen MJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 2014; 14: 147.
3. Rossetti CA, Arenas-Gamboa AM, Maurizio E. Caprine brucellosis: A historically neglected disease with significant impact on public health. PLoS Negl Trop Dis. 2017; 11: e0005692.

4. Robinson A. Surveillance of human brucellosis. Robinson A (ed). Guidelines for coordinated human and animal brucellosis surveillance. Emergency Prevention System & Food and Agriculture Organization of the United Nations. Rome, 2003, 11-12.
5. Facciola A, Palamara MAR, D'Andrea G, Marano F, Magliariti D, Puglisi G, et al. Brucellosis is a public health problem in southern Italy: Burden and epidemiological trend of human and animal disease. *J Infect Public Health*. 2018; 11: 861-866.
6. Durusoy R, Karababa AO. Completeness of hepatitis, brucellosis, syphilis, measles and HIV/AIDS surveillance in Izmir, Turkey. *BMC Public Health*. 2010; 10: 71.
7. European Food Safety Authority and European Centre for Disease Prevention and Control (EFSA and ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. *EFSA Journal*. 2018; 16: 5500, available at: <https://www.efsa.europa.eu/en/efsajournal/pub/5500>, date accessed: 30/06/2019.
8. Mellou K, Sideroglou T, Kallimani A, Potamiti-Komi M, Pervanidou D, Lillakou E, et al. Evaluation of underreporting of salmonellosis and shigellosis hospitalised cases in Greece, 2011: results of a capture-recapture study and a hospital registry review. *BMC Public Health*. 2013; 13: 875.
9. Jelastopulu E, Merekoulias G, Alexopoulos EC. Underreporting of communicable diseases in the prefecture of Achaia, western Greece, 1999-2004 - missed opportunities for early intervention. *Euro Surveill*. 2010; 15: 19579.
10. Avdikou I, Maipa V, Alamanos Y. Epidemiology of human brucellosis in a defined area of Northwestern Greece. *Epidemiol Infect*. 2005; 133: 905-910.
11. Eurostat. Methodology. Available at: <https://ec.europa.eu/eurostat/web/rural-development/methodology>, date accessed: 30/06/2019.
12. Eurostat. Local Administrative Units. Available at: <https://ec.europa.eu/eurostat/web/nuts/local-administrative-units>, date accessed: 30/06/2019.
13. Chao A, Tsay PK, Lin SH, Shau WY, Chao DY. The applications of capture-recapture models to epidemiological data. *Stat Med*. 2001; 20: 3123-3157.
14. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. *PLoS Negl Trop Dis*. 2012; 6: e1865.
15. Figueiras A, Lado E, Fernández S, Hervada X. Influence of physicians' attitudes on under-notifying infectious diseases: a longitudinal study. *Public Health*. 2004; 118: 521-526.
16. Benson FG, Levin J, Rispel LC. Health care providers' compliance with the notifiable diseases surveillance system in South Africa. *Plos One*. 2018; 13: e0195194.
17. Savage RD, Rosella LC, Brown KA, Khan K, Crowcroft NS. Underreporting of hepatitis A in non-endemic countries: a systematic review and meta-analysis. *BMC Infect Dis*. 2016; 16: 281.
18. Brabazon ED, O'Farrell A, Murray CA, Carton MW, Finnegan P. Under-reporting of notifiable infectious disease hospitalizations in a health board region in Ireland: room for improvement? *Epidemiol Infect*. 2008; 136: 241-247.
19. Abdulrahim N, Alasasfeh I, Khader YS, Iblan I. Knowledge, Awareness, and Compliance of Disease Surveillance and Notification Among Jordanian Physicians in Residency Programs. *Inquiry*. 2019; 56: 46958019856508.
20. Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. *Indian J Med Microbiol*. 2007; 25: 188-202.
21. Al Dahouk S, Nöckler K. Implications of laboratory diagnosis on brucellosis therapy. *Expert Rev Anti Infect Ther*. 2011; 9: 833-845.
22. Guzmán-Bracho C, Salgado-Jiménez B, Beltrán-Parra LG, Hernández-Monroy I, Vargas-Pino F, Rodríguez D, et al. Evaluation of serological diagnostic tests of human brucellosis for prevention and control in Mexico. *Eur J Clin Microbiol Infect Dis*. 2020; 39: 575-581.
23. Baldi PC, Miguel SE, Fossati CA, Wallach JC. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of *Brucella* species. *Clin Infect Dis*. 1996; 22: 446-455.
24. Serra J, Viñas M. Laboratory diagnosis of brucellosis in a rural endemic area in northeastern Spain. *Int Microbiol*. 2004; 7: 53-58.
25. Yagupsky P. Detection of *Brucella melitensis* by BACTEC NR660 blood culture system. *J Clin Microbiol*. 1994; 32: 1899-1901.
26. Yagupsky P. Blood Cultures for the Diagnosis of Human Brucellosis. Baddour MM (eds). *Updates on Brucellosis*. 1<sup>st</sup> Edition. IntechOpen Limited, London, 2015, 103-124.
27. Gupte S, Kaur T. Diagnosis of Human Brucellosis. *J Trop Dis*. 2015; 04: 185.